Diplomat acquires Focus Rx
FLINT, Mich. — Diplomat Pharmacy has a new addition to its ranks. The company on Monday announced the closing of its acquisition of Focus Rx Pharmacy Services, a New York-based specialty and infusion pharmacy with two locations in the state.
Focus Rx offers home infusion and specialty prescription management services, and its acquisition will strengthen Diplomat’s ability to deliver solutions for increasing infusion therapy demand, the company said.
“This partnership opens growth opportunities, especially in the key markets of New York and New Jersey,” Diplomat VP and president of Diplomat Specialty Infusion Group Phil Rielly said. “Focus Rx brings over 15 regional and national payor contracts, boosting Diplomat’s prescription and payer access.”
Diplomat said Focus Rx’s nutrition deficiency business would complement its existing Thrive Rx nutrition division of Diplomat Specialty Infusion Group, offering growth in the New York market. The company expects Focus Rx to generate roughly $47 million in revenue and $3 million in earnings before interest, taxes, depreciation and amortization for the full year 2017.
“As a specialty infusion provider in today’s rapidly evolving health care environment, we are excited to partner with Diplomat to enhance the delivery of comprehensive and personalized services to our patients,” Focus Rx CEO Lou Puleo said. “Our efforts improve patient results, as well as the clinical, operational, and financial well-being of our partners. Diplomat will further our commitment, enabling us to deliver integrated health care services to new and existing consumers and advancing our strong clinical expertise.”
NACDS touts in-district RxImpact efforts
ALEXANDRIA, Va. — With Congress back from its August recess, the National Association of Chain Drug Stores has shared some data about the efforts it made to reach out to lawmakers in their district. The organization said that more than half of NACDS RxImpact 2017 activities allowed advocates access to legislators who support pharmacist provider status, and that almost 20% signed on to support the bill following the in-district efforts.
Roughly 31% of NACDS member companies took part in the activities, 79% of which were tours of members pharmacies with lawmakers. About 18% of the activities were town hall meetings.
NACDS’ efforts brought them in contact with 43% of all newly elected members of Congress, and 69% of lawmakers with whom NACDS RxImpact has had no previous in-district contact. Overall, advocates reached 32% of the Senate, 44% of which were Democrats and 56% of which were Republicans.
In terms of Senate decision makers, NACDS said that its in-district efforts brought them in contact with 35% of the Senate Finance Committee, 30% of the Senate Armed Forces Committee and 26% of the Senate Health, Education Labor and Pensions Committee.
Lupin gets FDA approval for Vibra-Tabs generic
SILVER SPRING, Md. — The Food and Drug Administration has approved Lupin’s generic of Pfizer’s Vibra-Tabs (doxycycline hyclate) tablets. The drug is indicatd to treat infections caused by various microorganisms and as an adjunctive therapy for severe acne.
Lupin’s generic will be available in 100-mg dosage strength. The drug had U.S. sales of $149.9 million for the 12 months ended June 2017, according to QuintilesIMS data.